---
layout: default
title: Alpha -Tocopherol Acetate Hydrogen Peroxide Silico
parent: 僅模型預測 (L5)
nav_order: 231
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Acetate Hydrogen Peroxide Silico
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alpha-Tocopherol Acetate / Hydrogen Peroxide / Silicon Dioxide: Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This entry represents a multi-ingredient combination — alpha-tocopherol acetate (Vitamin E), hydrogen peroxide (antiseptic/oxidizing agent), and silicon dioxide (excipient/abrasive) — commonly found in oral care or topical antiseptic formulations.
The TxGNN model returned **no predicted new indications** for this compound combination, and the drug holds **no US regulatory approvals** in the current dataset.
With no clinical trial evidence, no literature, and no original approved indication on record, this candidate **cannot be meaningfully evaluated** for drug repurposing at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 — no prediction generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why No Prediction Was Generated

This combination presents several structural challenges for the TxGNN model:

**Component mismatch with DrugBank knowledge graph.** TxGNN operates on single DrugBank-mapped entities. A co-formulated mixture of three components — particularly when one (silicon dioxide) is a pharmacologically inert excipient — cannot be cleanly represented as a single node in the disease–drug knowledge graph. The DrugBank ID for this combination is absent, which effectively prevents the model from identifying mechanistic disease linkages.

**Hydrogen peroxide and alpha-tocopherol as individual agents are well-characterized, but not as a fixed combination.** Hydrogen peroxide exerts its effect through reactive oxygen species generation (antimicrobial, bleaching), while alpha-tocopherol acetate acts as a lipid-soluble antioxidant. These two mechanisms are pharmacologically divergent, and their combination is typically formulated for local-use applications (e.g., dental whitening, wound antisepsis) rather than systemic disease treatment — further limiting the relevance of a systemic repurposing prediction.

**No approved indication provides anchor context.** Without a known original indication, TxGNN has no disease-similarity pathway to explore for candidate expansion.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This combination lacks a DrugBank ID, has no regulatory approvals, and produced no TxGNN predictions. It does not meet the minimum data requirements for repurposing evaluation. Proceeding without further data resolution would not yield actionable results.

**To proceed, the following is needed:**

- **Clarify compound identity**: Determine whether this is intended as a fixed-dose combination product or whether each component should be evaluated independently. If individual evaluation is intended, run separate Evidence Pack queries for alpha-tocopherol acetate (DB00163) and hydrogen peroxide (DB09143).
- **Resolve original indication**: Identify the therapeutic context (e.g., oral antiseptic, wound care, dermatological) to anchor any repurposing analysis.
- **Obtain DrugBank mapping**: Without a DrugBank ID, TxGNN knowledge graph traversal is not possible. Manual mapping or decomposition into individual components is required.
- **Retrieve safety package insert data**: TFDA or equivalent regulatory source should be queried to obtain contraindications and warnings, particularly given hydrogen peroxide's tissue-reactivity profile.
- **Reconsider scope**: If the interest is in **alpha-tocopherol acetate** as a repurposing candidate (e.g., for neurodegenerative disease, NASH, or cancer adjuvant), consider submitting a dedicated single-drug Evidence Pack.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

